Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

This Metric Says You Are Smart to Buy Genpact Limited (NYSE:G)

Genpact Limited (NYSE:G) has experienced an increase in support from the world’s most elite money managers recently.

Genpact Limited (NYSE:G)

According to most investors, hedge funds are seen as unimportant, old investment vehicles of years past. While there are more than 8000 funds with their doors open today, we at Insider Monkey look at the elite of this group, about 450 funds. It is widely believed that this group controls most of the smart money’s total capital, and by keeping an eye on their top equity investments, we have determined a few investment strategies that have historically outpaced the market. Our small-cap hedge fund strategy beat the S&P 500 index by 18 percentage points per year for a decade in our back tests, and since we’ve started sharing our picks with our subscribers at the end of August 2012, we have outpaced the S&P 500 index by 25 percentage points in 6.5 month (see all of our picks from August).

Just as key, positive insider trading sentiment is another way to break down the marketplace. As the old adage goes: there are lots of stimuli for a bullish insider to sell shares of his or her company, but just one, very clear reason why they would buy. Plenty of empirical studies have demonstrated the impressive potential of this method if you understand what to do (learn more here).

Consequently, it’s important to take a peek at the latest action regarding Genpact Limited (NYSE:G).

Hedge fund activity in Genpact Limited (NYSE:G)

Heading into 2013, a total of 16 of the hedge funds we track were long in this stock, a change of 14% from one quarter earlier. With hedge funds’ capital changing hands, there exists an “upper tier” of key hedge fund managers who were boosting their holdings considerably.

When looking at the hedgies we track, Eminence Capital, managed by Ricky Sandler, holds the biggest position in Genpact Limited (NYSE:G). Eminence Capital has a $99 million position in the stock, comprising 2.9% of its 13F portfolio. On Eminence Capital’s heels is Royce & Associates, managed by Chuck Royce, which held a $20 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Other peers with similar optimism include Jim Simons’s Renaissance Technologies, Ken Griffin’s Citadel Investment Group and SAC Subsidiary’s Sigma Capital Management.

As industrywide interest jumped, some big names have jumped into Genpact Limited (NYSE:G) headfirst. Sigma Capital Management, managed by SAC Subsidiary, created the most valuable position in Genpact Limited (NYSE:G). Sigma Capital Management had 10 million invested in the company at the end of the quarter. James Dinan’s York Capital Management also initiated a $6 million position during the quarter. The other funds with brand new G positions are John Overdeck and David Siegel’s Two Sigma Advisors and Daniel S. Och’s OZ Management.

How have insiders been trading Genpact Limited (NYSE:G)?

Insider buying is most useful when the company in question has seen transactions within the past six months. Over the last half-year time period, Genpact Limited (NYSE:G) has experienced zero unique insiders buying, and 27 insider sales (see the details of insider trades here).

With the results demonstrated by our time-tested strategies, everyday investors must always monitor hedge fund and insider trading activity, and Genpact Limited (NYSE:G) shareholders fit into this picture quite nicely.

Click here to learn more about Insider Monkey’s Hedge Fund Newsletter

Insider Monkey’s small-cap strategy returned 29.2% between September 2012 and February 2013 versus 8.7% for the S&P 500 index. Try it now by clicking the link above.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!